← Top stories
Broker call▼ Bearish for Apollo Hospitals
Could Apollo, Fortis, Max Health Face A Profit Hit From Medicine Price Curbs? Jefferies, BofA, Macquarie Weigh In
The brief
- The Court questioned the spread between medicine purchase prices and MRP
- It questioned whether the 16% margin cap for scheduled drugs could be extended
- A wider price cap could pressure Apollo Hospitals, Fortis and Max Healthcare margins
- Max Healthcare Institute among 3 F&O stocks with a sharp rise in futures open interest
- Top 2 stocks to buy or sell for short-term: Cyient, Max Healthcare by Nagaraj Shetti - Check stop loss, targets
- Market wrap: Kotak Mahindra Bank, InterGlobe, Apollo Hospital, Max Healthcare top gainers and losers on Nifty and Sensex on Wednesday
- Stocks making the biggest moves midday: Apollo Hospitals, Max Health, Rail Vikas, and more
- Firstsource Solutions, Solar Industries lead Nifty 500 gainers, Max Healthcare, BSE fall at market open
Hospital drug markups and pricing regulation concerns
The Supreme Court questioned hospital markups on cancer drugs, including a case where a medicine costing ₹2,700 to retailers was billed at ₹27,000 to patients, and urged a probe. Hospital stocks fell sharply, erasing $2.6 billion in value, as investors weighed possible medicine price curbs.
Thursday, 1 October
- Could Apollo, Fortis, Max Health Face A Profit Hit From Medicine Price Curbs? Jefferies, BofA, Macquarie Weigh In